Abstract
Cannabis has been used for millennia for its health and recreational merits; however, the 'high' produced by cannabis consumption is an unwanted side effect for medicinal cannabis users {1}. Therefore, researchers have begun to focus on how to harness the beneficial effects of cannabinoids without exposing the patient to unwanted psychotropic effects. Two cannabinoid receptors (CBs) have been implicated in the majority of cannabis' effects. CB1 is primarily located on neural tissue and is responsible for the psychotropic effects of cannabis {2}. Conversely, CB2 activation does not affect cognitive function, as it is primarily expressed on peripheral tissues {3}. In joints, CB2 receptors are expressed on synovial tissue and nerves {4}, where their activation includes, but is not limited to, an ability to reduce pain {4}, attenuate synovial inflammation {5}, and reduce bone resorption {6}. The aim of the study by Gui et al. was to investigate if a potent and selective CB2 agonist, HU308, could decrease disease severity in a mouse model of rheumatoid arthritis. This study utilized the collagen induced arthritis model, and assessed inflammation, as well as joint destruction, with or without HU308 treatment (0.3 or 1.0mg/kg; i.p.; once a day for 7 days). High dose HU308 (1.0mg/kg), but not low dose (0.3mg/kg), significantly reduced clinical arthritis scores when compared to vehicle. Furthermore, upon histological assessment, high dose HU308 reduced inflammatory cell infiltration into the synovium and pannus formation. When cartilage and bone damage was assessed, HU308 (1.0mg/kg) attenuated demineralization, joint space narrowing and erosion. In addition to its effectiveness in the joint, HU308 (1.0mg/kg) significantly decreased serum levels of type II collagen antibodies, which are essential for arthritic autoimmunity in this model. Lastly, in vitro, HU308 (1-10μM) significantly decreased interleukin-6 and tumor necrosis factor-α production from lipopolysaccharide-stimulated macrophages, indicating that CB2 receptor agonism can reduce the production of pro-inflammatory mediators. One limitation of this study was that behavioural pain responses were not measured. CB2 agonists are capable of sensitizing arthritic joint afferents {4}; therefore, the protective effects of CB2 activation may be offset by adverse pro-nociceptive effects. Future studies should identify the effects of HU308 on arthritic pain. These results provide evidence that HU308, a CB2 specific agonist, can protect the joint from the effects of inflammation. By specifically targeting CB2, it may be possible to tap into the beneficial effects of the cannabinoid system without unwanted psychotropic effects.